IAMA Therapeutics develops small molecules that selectively inhibit cation-chloride cotransporters to address atypical brain activity in autism, epilepsies, and other central nervous system disorders. Their approach leverages advances in neuroscience drug discovery and precision medicine to create targeted therapeutics for unmet medical needs.
Funding
$8.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many central nervous system disorders, such as autism and epilepsy, are characterized by atypical brain activity. Current treatment options often lack specificity and efficacy in addressing the underlying causes of these disorders.
Solution
IAMA Therapeutics is developing a pipeline of small molecule therapeutics designed to selectively inhibit cation-chloride cotransporters (CCCs). By targeting CCCs, IAMA aims to restore typical brain activity in patients with autism, epilepsies, and other CNS disorders. Their approach combines advances in neuroscience drug discovery with precision medicine to create targeted therapeutics that address unmet medical needs in neurological conditions.
Target Audience
The primary target audience includes individuals affected by autism, epilepsies, and other central nervous system disorders, as well as the healthcare professionals who treat them.
Features
- Small molecule therapeutics designed for CNS disorders
- Selective inhibition of cation-chloride cotransporters (CCCs)
- Aims to rescue atypical brain activity in neurological conditions
- Pipeline of novel therapeutics for autism, epilepsies, and other CNS disorders